{"status":"OK","data":{"advertisement":{"id":395202,"title":"Opracowanie i rozw\u00f3j innowacyjnego rozwi\u0105zania \u2013 z\u0142o\u017conego, dwusk\u0142adnikowego produktu leczniczego, ukierunkowanego na terapi\u0119 nadci\u015bnienia t\u0119tniczego\u201d w ramach programu Fundusze Europejskie dla Nowoczesnej Gospodarki 2021-2027, dzia\u0142anie \u201e\u015acie\u017cka SMART\u201d, w ramach 1 Priorytetu \u201eWsparcie dla przedsi\u0119biorc\u00f3w\u201d.\n\nDevelopment and development of an innovative solution \u2013 a complex, two-component medicinal product aimed at the therapy of hypertension\" under the European Funds for Modern Economy 2021-2027 programme, the \"SMART Path\" measure, under Priority 1 \"Support for entrepreneurs\".","partial_offer_allowed":false,"publication_date":"2026-11-13","submission_deadline":"2026-11-23 23:59:59","planned_sign_date":"2026-12-01","supplementary_orders":"Szczeg\u00f3\u0142owe informacje w za\u0142\u0105czniku: \"Zapytanie ofertowe\". \nW PRZYPADKU ROZBIE\u017bNO\u015aCI POMI\u0118DZY TRE\u015aCI\u0104 OG\u0141OSZENIA O ZAM\u00d3WIENIU A TRE\u015aCI\u0104 ZAPYTANIA OFERTOWEGO (STANOWI\u0104CEGO ZA\u0141\u0104CZNIK DO OG\u0141OSZENIA O ZAM\u00d3WIENIU), TRE\u015a\u0106 ZAPYTANIA OFERTOWEGO JEST WI\u0104\u017b\u0104CA.\n\nDetailed information is attached: \"Request for Proposal\". \nIN THE EVENT OF A DISCREPANCY BETWEEN THE CONTENT OF THE CONTRACT NOTICE AND THE CONTENT OF THE REQUEST FOR PROPOSAL (WHICH IS AN ATTACHMENT TO THE CONTRACT NOTICE), THE CONTENT OF THE REQUEST FOR PROPOSAL IS BINDING.","terms_of_contract_change":"Zmiany umowy wprowadzane b\u0119d\u0105 w formie aneksu podpisanego przez obie strony, a mo\u017cliwo\u015b\u0107 ich wprowadzenia uzale\u017cniona jest od akceptacji przez Zamawiaj\u0105cego.\nSzczeg\u00f3\u0142owe informacje w za\u0142\u0105czniku: \"Zapytanie ofertowe\". \n\nChanges to the contract will be introduced in the form of an annex signed by both parties, and the possibility of their introduction depends on the acceptance by the Ordering Party.\nDetailed information is attached: \"Request for Proposal\".","created_at":"2026-11-13 12:32:30","modified_at":"2026-11-13 12:33:07","contact_persons":[{"id":127778,"forename":"Micha\u0142","surname":"Kobylski","phone_number":"","email":"michal.kobylski@polpharma.com","created_by":null,"created_at":"2026-11-13 12:32:30","modified_at":"2026-11-13 12:32:30","modified_by":null}],"orders":[{"id":640461,"estimated_value":null,"order_items":[{"id":720086,"description":"LERCAN/7/PR 177991/ 2026-130337-293977\nRealizacja us\u0142ugi badawczej polegaj\u0105cej na kompleksowym przeprowadzeniu retrospektywnego badania typu Real-World Evidence (RWE) w obszarze nadci\u015bnienia t\u0119tniczego, realizowanego na potrzeby regulacyjne tj. zgodnie z aktualnymi wymaganiami organ\u00f3w regulacyjnych, celem wykorzystania wynik\u00f3w badania w ocenie stosunku korzy\u015bci do ryzyka w procesie rejestracji leku. \n\nW dniu 13.11.2026r w zwi\u0105zku z udzielonymi odpowiedziami na pytania dokonano zmiany terminu ofert na 23.11.2026r.\nZa\u0142\u0105czono plik ze zmian\u0105 tre\u015bci zapytania\n\nSzczeg\u00f3\u0142owe informacje w za\u0142\u0105czniku: \"Zapytanie ofertowe\". \n\nImplementation of a research service consisting in a comprehensive retrospective Real-World Evidence (RWE) test in the area of hypertension, carried out for regulatory purposes, i.e. in accordance with the current requirements of regulatory authorities, in order to use the results of the study in the assessment of the benefit-risk ratio in the drug registration process.\n\nDetailed information is attached: \"Request for Proposal\".\n\nOn 13.11.2026, in connection with the answers to the questions, the deadline for the offers was changed to 23.11.2026. \nAttached a file with a change in the content of the query","warranty_period":null,"cpv_items":[{"id":8453,"code":"72310000-1","name":"Us\u0142ugi przetwarzania danych"},{"id":8466,"code":"72316000-3","name":"Us\u0142ugi analizy danych"},{"id":8469,"code":"72319000-4","name":"Us\u0142ugi dostarczania danych"},{"id":8470,"code":"72320000-4","name":"Us\u0142ugi bazy danych"},{"id":8512,"code":"73000000-2","name":"Us\u0142ugi badawcze i eksperymentalno-rozwojowe oraz pokrewne us\u0142ugi doradcze"},{"id":8514,"code":"73110000-6","name":"Us\u0142ugi badawcze"}],"timetable_items":[],"fulfillment_places":[{"country":"Polska","voivodeship":null,"poviat":null,"commune":null,"locality":null,"created_by":null,"created_at":"2026-11-13 12:32:30","modified_at":"2026-11-13 12:32:30","modified_by":null,"id":821120,"type":{"id":2,"name":"ca\u0142a Polska"},"group_uuid":"0912bfb9-da8a-4f85-abe8-815b2a128b54"}],"participation_conditions":[{"id":2061613,"description":"Zamawiaj\u0105cy uzna warunek za spe\u0142niony, je\u017celi Oferent wyka\u017ce, \u017ce posiada wiedz\u0119 i do\u015bwiadczenie niezb\u0119dne do prawid\u0142owej realizacji zam\u00f3wienia, w szczeg\u00f3lno\u015bci w zakresie projektowania, realizacji, analizy i raportowania bada\u0144 wykorzystuj\u0105cych dane rzeczywiste (Real-World Data), bada\u0144 obserwacyjnych, farmakoepidemiologicznych lub innych bada\u0144 nieinterwencyjnych o por\u00f3wnywalnym charakterze, opartych na danych medycznych, rejestrowych, administracyjnych lub pochodz\u0105cych z innych \u017ar\u00f3de\u0142 danych rzeczywistych.\n\nW celu potwierdzenia spe\u0142nienia warunku Oferent przedstawi wykaz us\u0142ug wykonanych w okresie ostatnich 10 lat przed up\u0142ywem terminu sk\u0142adania ofert, a je\u017celi okres prowadzenia dzia\u0142alno\u015bci jest kr\u00f3tszy, w tym okresie, obejmuj\u0105cy co najmniej:\n\n\u2022\trealizacj\u0119 minimum 5 bada\u0144 typu Real-World Evidence (RWE), bada\u0144 obserwacyjnych, farmakoepidemiologicznych lub bada\u0144 r\u00f3wnowa\u017cnych pod wzgl\u0119dem zakresu, celu i stosowanej metodologii;\n\u2022\trealizacj\u0119 minimum 3 projekt\u00f3w obejmuj\u0105cych analiz\u0119 danych rzeczywistych z wykorzystaniem elektronicznej dokumentacji medycznej, rejestr\u00f3w, baz danych administracyjnych, danych refundacyjnych, ubezpieczeniowych lub innych por\u00f3wnywalnych \u017ar\u00f3de\u0142 danych;\n\u2022\tprzygotowanie dokumentacji badawczej, obejmuj\u0105cej co najmniej protok\u00f3\u0142 badania, plan analizy statystycznej, raport statystyczny oraz raport ko\u0144cowy;\n\u2022\tzastosowanie metod analitycznych s\u0142u\u017c\u0105cych ograniczaniu wp\u0142ywu czynnik\u00f3w zak\u0142\u00f3caj\u0105cych w badaniach nieinterwencyjnych;\n\u2022\trealizacj\u0119 minimum 3 bada\u0144 dotycz\u0105cych efektywno\u015bci farmakoterapii w obszarze kardiologii lub hipertensjologii.\n\nPreferowane b\u0119dzie do\u015bwiadczenie w realizacji bada\u0144 RWE lub bada\u0144 retrospektywnych prowadzonych na potrzeby regulacyjne, w tym bada\u0144 zgodnych z wytycznymi EMA, ICH, ENCePP, STROBE lub RECORD-PE.\n\nSpos\u00f3b oceny warunku: \nWeryfikacja nast\u0105pi w oparciu o o\u015bwiadczenie Oferenta o spe\u0142nianiu warunk\u00f3w udzia\u0142u w post\u0119powaniu, zawarte w za\u0142\u0105czniku nr 1 (Formularz ofertowy) oraz za\u0142\u0105czonego wraz z ofert\u0105 wykazu zrealizowanych us\u0142ug, projekt\u00f3w lub bada\u0144 potwierdzaj\u0105cych posiadanie wymaganego do\u015bwiadczenia w ci\u0105gu ostatnich 10 lat dzia\u0142alno\u015bci.\n\nWykaz musi zawiera\u0107 informacje umo\u017cliwiaj\u0105ce Zamawiaj\u0105cemu ocen\u0119 spe\u0142niania warunku, w szczeg\u00f3lno\u015bci:\n\u2022\trok realizacji, \n\u2022\tdziedzina medycyny (np. kardiologia, hipertensjologia), \n\u2022\tcharakter badania (interwencyjny/obserwacyjny, prospektywny/retrospektywny), \n\u2022\tprodukty badane (na drugim poziomie klasyfikacji ATC, np. C08 \u2013 antagonisty kana\u0142u wapniowego)\n\u2022\ttyp zastosowanych danych (np. dokumentacja medyczna/dane refundacyjne) \u2013 je\u017celi dotyczy\n\u2022\tzakres wykonanych prac (np. pe\u0142na realizacja badania/studium wykonalno\u015bci/doradztwo naukowe/pisarstwo medyczne/analiza danych/analiza statystyczna/analiza kliniczna)\n\nZamawiaj\u0105cy dopu\u015bci r\u00f3wnie\u017c wykazanie do\u015bwiadczenia r\u00f3wnowa\u017cnego, tj. zdobytego przy realizacji projekt\u00f3w o por\u00f3wnywalnym zakresie, charakterze, stopniu z\u0142o\u017cono\u015bci i celu do wskazanych w warunku udzia\u0142u w post\u0119powaniu.\n\nThe Contracting Authority shall consider the condition to be met if the Tenderer demonstrates that it has the knowledge and experience necessary for the proper performance of the contract, in particular in the field of design, implementation, analysis and reporting of studies using real data (Real-World Data), observational studies, pharmacoepidemiological studies or other non-interventional studies of a comparable nature, based on medical, registry, administrative or other sources of real data. \n\nIn order to confirm the fulfilment of the condition, the Bidder shall submit a list of services performed in the period of the last 10 years prior to the expiry of the deadline for submission of tenders, and if the period of operation is shorter, in this period, covering at least: \n\n\u2022 implementation of a minimum of 5 Real-World Evidence (RWE) studies, observational studies, pharmacoepidemiological studies or equivalent studies in terms of scope, purpose and methodology used; \n\u2022 implementation of at least 3 projects involving the analysis of real data using electronic medical records, registers, administrative databases, reimbursement data, insurance data or other comparable data sources; \n\u2022 preparation of research documentation, including at least the study protocol, statistical analysis plan, statistical report and final report; \n\u2022 use of analytical methods to reduce the impact of confounding factors in non-interventional studies; \n\u2022 implementation of at least 3 studies on the effectiveness of pharmacotherapy in the field of cardiology or hypertension. \n\nPreference will be given to experience in conducting RWE studies or retrospective studies conducted for regulatory purposes, including studies compliant with EMA, ICH, ENCePP, STROBE or RECORD-PE guidelines. \n\nMethod of assessment of the condition: \nThe verification will take place on the basis of the Bidder's statement on meeting the conditions for participation in the procedure, contained in Appendix No. 1 (Offer Form) and the list of services, projects or studies provided with the offer, confirming the required experience in the last 10 years of activity. \n\nThe list must contain information enabling the Contracting Authority to assess the fulfilment of the condition, in particular: \n\u2022 year of implementation, \n\u2022 the field of medicine (e.g. cardiology, hypertension), \n\u2022 the nature of the study (interventional/observational, prospective/retrospective), \n\u2022 test products (at the second level of ATC classification, e.g. C08 \u2013 calcium channel antagonist)\n\u2022 type of data used (e.g. medical records/reimbursement data) \u2013 if applicable\n\u2022 scope of work performed (e.g. full implementation of the study/feasibility study/scientific advice/medical writing/data analysis/statistical analysis/clinical analysis)\n\nThe contracting authority will also allow demonstrating equivalent experience, i.e. gained during the implementation of projects of comparable scope, nature, complexity and objective to those indicated in the condition of participation in the procedur","type":{"id":2,"name":"Wiedza i do\u015bwiadczenie"},"created_by":null,"created_at":"2026-11-13 12:32:30","modified_at":"2026-11-13 12:32:30","modified_by":null,"group_uuid":"c0f21bc7-2997-4e82-8d26-6a66ec8737b1"},{"id":2061614,"description":"Zamawiaj\u0105cy uzna, \u017ce Oferent spe\u0142nia niniejszy warunek, je\u017celi z\u0142o\u017cy o\u015bwiadczenie, \u017ce dysponuje i / lub b\u0119dzie dysponowa\u0142 na dzie\u0144 podpisania Umowy zapleczem technicznym niezb\u0119dnym do prawid\u0142owej realizacji zam\u00f3wienia.\nW szczeg\u00f3lno\u015bci Oferent musi posiada\u0107 lub zapewni\u0107:\n\u2022\tkomputery o mocy obliczeniowej, kt\u00f3re zapewni\u0105 p\u0142ynne dzia\u0142anie zaawansowanych program\u00f3w analitycznych i statystycznych;\n\u2022\tnarz\u0119dzia, procedury i \u015brodowisko pracy umo\u017cliwiaj\u0105ce bezpieczne przetwarzanie danych zgodnie z wymaganiami ochrony danych, zasadami poufno\u015bci oraz wymogami dysponenta danych;\n\u2022\tmo\u017cliwo\u015b\u0107 opracowania list kod\u00f3w, definicji operacyjnych, algorytm\u00f3w analitycznych i dokumentacji umo\u017cliwiaj\u0105cej powtarzalno\u015b\u0107 analiz;\n\u2022\tmo\u017cliwo\u015b\u0107 przeprowadzenia analizy statystycznej z wykorzystaniem standardowego, zwalidowanego lub powszechnie akceptowanego oprogramowania statystycznego;\n\u2022\tprocedury kontroli jako\u015bci i walidacji wynik\u00f3w analiz;\n\u2022\tmo\u017cliwo\u015b\u0107 przygotowania raport\u00f3w, tabel, wykres\u00f3w, listing\u00f3w i dokumentacji analitycznej w formacie umo\u017cliwiaj\u0105cym ich wykorzystanie w dokumentacji regulacyjnej.\n\nSpos\u00f3b oceny warunku: \nWeryfikacja nast\u0105pi w oparciu o o\u015bwiadczenie Oferenta o spe\u0142nianiu warunk\u00f3w udzia\u0142u w post\u0119powaniu, zawarte w za\u0142\u0105czniku nr 1 (Formularz ofertowy).\n\nNa \u017c\u0105danie Zamawiaj\u0105cego Oferent zobowi\u0105zany b\u0119dzie przedstawi\u0107 dodatkowe informacje lub dokumenty potwierdzaj\u0105ce spe\u0142nianie warunku udzia\u0142u w post\u0119powaniu w zakresie potencja\u0142u technicznego.\n\nThe Contracting Authority shall consider that the Tenderer fulfils this condition if it submits a declaration that it has and/or will have at its disposal on the date of signing the Agreement the technical facilities necessary for the proper performance of the contract. \nIn particular, the Bidder must have or provide: \n\u2022 computers with computing power that will ensure the smooth operation of advanced analytical and statistical programs; \n\u2022 tools, procedures and working environment enabling secure data processing in accordance with data protection requirements, confidentiality rules and the requirements of the data controller; \n\u2022 the ability to develop code lists, operational definitions, analytical algorithms and documentation enabling repeatability of analyses; \n\u2022 the ability to perform statistical analysis using standard, validated or widely accepted statistical software; \n\u2022 procedures for quality control and validation of analysis results; \n\u2022 the ability to prepare reports, tables, charts, listings and analytical documentation in a format that allows them to be used in regulatory documentation. \n\nMethod of assessment of the condition: \nThe verification will take place on the basis of the Bidder's statement on meeting the conditions for participation in the procedure, contained in Appendix No. 1 (Offer Form). \n\nAt the request of the Contracting Authority, the Bidder will be obliged to provide additional information or documents confirming the fulfilment of the condition of participation in the procedure in terms of technical potential.","type":{"id":3,"name":"Potencja\u0142 techniczny"},"created_by":null,"created_at":"2026-11-13 12:32:30","modified_at":"2026-11-13 12:32:30","modified_by":null,"group_uuid":"1546128c-c659-4f8c-b8cc-943f5fe2c771"},{"id":2061615,"description":"Zamawiaj\u0105cy uzna, \u017ce Oferent spe\u0142nia ten warunek, je\u017celi z\u0142o\u017cy o\u015bwiadczenie, \u017ce dysponuje i/lub b\u0119dzie dysponowa\u0142 w dniu podpisania Umowy odpowiednio wykwalifikowanym zespo\u0142em, kt\u00f3ry zostanie oddelegowany do realizacji zam\u00f3wienia, sk\u0142adaj\u0105cy si\u0119 co najmniej z: \n\u2022\tlider projektu naukowego;\n\u2022\tekspert naukowy lub farmakoepidemiolog odpowiedzialny za projekt badania RWE;\n\u2022\tg\u0142\u00f3wny statystyk;\n\u2022\tekspert ds. zarz\u0105dzania danymi lub data scientist;\n\u2022\tekspert kliniczny, tj. lekarz ze specjalizacj\u0105 z obszaru kardiologii lub hipertensjologii lub farmakologii klinicznej lub pokrewnego obszaru, posiadaj\u0105cy wiedz\u0119 dot. praktyki klinicznej z kraju pochodzenia proponowanej bazy danych (uzyskan\u0105 na drodze praktyki lekarskiej i/lub zaanga\u017cowania w badaniach obserwacyjnych) ;\n\u2022\tpisarz medyczny posiadaj\u0105cy do\u015bwiadczenie w przygotowywaniu dokumentacji na potrzeby regulacyjne (w tym protoko\u0142u badania obserwacyjnego lub interwencyjnego, raportu z badania obserwacyjnego lub interwencyjnego);\n\u2022\tosoba odpowiedzialna za kontrol\u0119 jako\u015bci dokumentacji i wynik\u00f3w.\n\n\nSpos\u00f3b oceny warunku: \nWeryfikacja nast\u0105pi w oparciu o o\u015bwiadczenie Oferenta o spe\u0142nianiu warunk\u00f3w udzia\u0142u w post\u0119powaniu, zawarte w za\u0142\u0105czniku nr 1 (Formularz ofertowy), oraz na \u017c\u0105danie Zamawiaj\u0105cego Oferent b\u0119dzie zobowi\u0105zany do przedstawienia wykazu kluczowych cz\u0142onk\u00f3w zespo\u0142u wraz z ich CV, potwierdzaj\u0105cymi pe\u0142nione funkcje, posiadane kwalifikacje oraz do\u015bwiadczenie.\n\nThe Contracting Authority shall consider that the Tenderer fulfils this condition if it submits a declaration that it has and/or will have at its disposal on the date of signing the Agreement a suitably qualified team that will be delegated to perform the contract, consisting of at least: \n\u2022 leader of a scientific project; \n\u2022 a scientific expert or pharmacoepidemiologist responsible for the RWE study project; \n\u2022 the main statistician; \n\u2022 Data management expert or data scientist; \n\u2022 a clinical expert, i.e. a physician specializing in cardiology or hypertension or clinical pharmacology or a related field, with knowledge of clinical practice from the country of origin of the proposed database (obtained through medical practice and/or involvement in observational studies); \n\u2022 A medical writer experienced in preparing regulatory documentation (including an observational or interventional study protocol, observational or interventional study report); \n\u2022 a person responsible for quality control of documentation and results. \n\n\nMethod of assessment of the condition: \nThe verification will take place on the basis of the Bidder's statement on meeting the conditions for participation in the procedure, contained in Appendix No. 1 (Offer Form), and at the request of the Ordering Party, the Bidder will be obliged to present a list of key team members along with their CVs, confirming the functions performed, qualifications and experience.","type":{"id":4,"name":"Osoby zdolne do wykonania zam\u00f3wienia"},"created_by":null,"created_at":"2026-11-13 12:32:30","modified_at":"2026-11-13 12:32:30","modified_by":null,"group_uuid":"3a0ed8b0-e0dd-4578-b71f-856234f57233"},{"id":2061616,"description":"Zamawiaj\u0105cy uzna, \u017ce Oferent spe\u0142nia niniejszy warunek, je\u017celi z\u0142o\u017cy o\u015bwiadczenie, \u017ce znajduje si\u0119 w sytuacji ekonomicznej i finansowej zapewniaj\u0105cej prawid\u0142ow\u0105 realizacj\u0119 zam\u00f3wienia, w szczeg\u00f3lno\u015bci nie znajduje si\u0119 w stanie upad\u0142o\u015bci, restrukturyzacji lub likwidacji, a tak\u017ce nie zalega w op\u0142acaniu podatk\u00f3w ani sk\u0142adek na ubezpieczenia spo\u0142eczne, ubezpieczenie zdrowotne, Fundusz Pracy i Fundusz Gwarantowanych \u015awiadcze\u0144 Pracowniczych.\n\nSpos\u00f3b oceny warunku: \nWeryfikacja nast\u0105pi w oparciu o o\u015bwiadczenie Oferenta o spe\u0142nianiu warunk\u00f3w udzia\u0142u w post\u0119powaniu, zawarte w za\u0142\u0105czniku nr 1 (Formularz ofertowy).\n\nThe Contracting Authority shall consider that the Tenderer fulfils this condition if it submits a declaration that it is in an economic and financial situation ensuring the proper performance of the contract, in particular it is not in a state of bankruptcy, restructuring or liquidation, and is not in arrears in the payment of taxes or contributions to social security, health insurance, the Labour Fund and the Guaranteed Employee Benefits Fund. \n\nMethod of assessment of the condition: \nThe verification will take place on the basis of the Bidder's statement on meeting the conditions for participation in the procedure, contained in Appendix No. 1 (Offer Form).","type":{"id":5,"name":"Sytuacja ekonomiczna i finansowa"},"created_by":null,"created_at":"2026-11-13 12:32:30","modified_at":"2026-11-13 12:32:30","modified_by":null,"group_uuid":"8471d332-7d70-4a1e-b79b-16569ce8f343"}],"category":{"id":1,"name":"Us\u0142uga"},"subcategory":{"id":4,"name":"Us\u0142ugi badawcze"},"created_by":null,"created_at":"2026-11-13 12:32:30","modified_at":"2026-11-13 12:32:30","modified_by":null,"group_uuid":"01a93e7a-c9d8-4a03-8801-962f97c8beab"}],"evaluation_criteria":[{"id":1155617,"price_criterion":true,"description":"Przy ocenianiu ofert Zamawiaj\u0105cy b\u0119dzie kierowa\u0142 si\u0119 podanymi poni\u017cej kryteriami:\n-\tCena \u2013 80%\n\n\nWhen evaluating the bids, the Contracting Authority will be guided by the following criteria: \n- Price \u2013 80%","created_by":null,"created_at":"2026-11-13 12:32:30","modified_at":"2026-11-13 12:32:30","modified_by":null,"group_uuid":"de2839db-af24-4326-a572-8954d11a912d"},{"id":1155618,"price_criterion":false,"description":"Przy ocenianiu ofert Zamawiaj\u0105cy b\u0119dzie kierowa\u0142 si\u0119 podanymi poni\u017cej kryteriami:\n-\tCzas realizacji us\u0142ugi \u2013 20%\n\nWhen evaluating the bids, the Contracting Authority will be guided by the following criteria: \n- Service delivery time \u2013 20%","created_by":null,"created_at":"2026-11-13 12:32:30","modified_at":"2026-11-13 12:32:30","modified_by":null,"group_uuid":"6f32aff6-edc1-417b-8236-b3abb6ba8293"}],"is_variant":false,"title":"LERCAN/7/PR 177991/ 2026-130337-293977","order_node":{"id":475529},"created_by":null,"created_at":"2026-11-13 12:32:30","modified_at":"2026-11-13 12:32:30","modified_by":null}],"created_by":{"id":130337,"contact_persons":[]},"modified_by":{"id":130337,"contact_persons":[]},"status":{"id":2,"label":"PUBLISHED","name":"Opublikowane"},"advertiser_address_details":{"name":"Zak\u0142ady Farmaceutyczne Polpharma S.A.","identification_number_type":"nip","identification_number":"5920202822","address":{"country":"Polska","voivodeship":"pomorskie","poviat":"starogardzki","commune":"Starogard Gda\u0144ski","locality":"Starogard Gda\u0144ski","created_by":{"id":130337,"contact_persons":[]},"created_at":"2026-11-13 12:32:30","modified_at":"2026-11-13 12:32:30","modified_by":{"id":130337,"contact_persons":[]},"id":1125087,"street":"Pelpli\u0144ska","number_description":"19","postcode":"83-200"},"created_by":{"id":130337,"contact_persons":[]},"created_at":"2026-11-13 12:32:30","modified_at":"2026-11-13 12:32:30","modified_by":{"id":130337,"contact_persons":[]},"id":396278},"advertisement":{"id":293977,"number":"2026-130337-293977","publication_date":"2026-10-12","created_by":{"id":130337,"contact_persons":[]},"created_at":"2026-10-06 13:31:01","modified_at":"2026-11-13 12:33:07","modified_by":{"id":130337,"contact_persons":[]},"status":{"id":2,"label":"PUBLISHED","name":"Opublikowane"},"all_available_version_ids":[389650,395202],"enrollment":null,"projects":[{"id":75585,"name":"Opracowanie i rozw\u00f3j innowacyjnego rozwi\u0105zania \u2013 z\u0142o\u017conego, dwusk\u0142adnikowego produktu leczniczego, ukierunkowanego na terapi\u0119 nadci\u015bnienia t\u0119tniczego.","number":"AOST/24","activity":{"created_by":{"modified_by":null,"id":89,"contact_persons":[]},"created_at":"2023-02-01 09:22:25","modified_at":"2023-02-01 09:22:25","modified_by":{"modified_by":null,"id":89,"contact_persons":[]}},"region":null,"institution":{"created_by":{"modified_by":null,"id":89,"contact_persons":[]},"created_at":"2023-02-01 09:27:55","modified_at":"2023-02-01 09:27:55","modified_by":{"modified_by":null,"id":89,"contact_persons":[]}},"full_number":"FENG.01.01-IP.01-AOST/24","perspective":{},"programme":{"created_by":{"modified_by":null,"id":89,"contact_persons":[]},"created_at":"2023-02-01 09:21:41","modified_at":"2023-02-01 09:21:41","modified_by":{"modified_by":null,"id":89,"contact_persons":[]}},"priority":{"created_by":{"modified_by":null,"id":89,"contact_persons":[]},"created_at":"2023-02-01 09:21:51","modified_at":"2023-02-01 09:21:51","modified_by":{"modified_by":null,"id":89,"contact_persons":[]}},"type":"project","created_by":{"id":130337,"contact_persons":[]},"created_at":"2026-10-05 15:03:50","modified_at":"2026-10-05 15:03:50","modified_by":{"id":130337,"contact_persons":[]}}],"is_author":false,"is_admin":false},"attachments":[{"origin":{"id":389650,"publication_date":"2026-10-12"},"id":2823681,"name":"ZAPYTANIE OFERTOWE nr LERCAN_7_PR_177991_2026-130337-293977.pdf","file":{"id":3133677,"name":"ZAPYTANIE OFERTOWE nr LERCAN_7_PR_177991_2026-130337-293977.pdf","created_at":"2026-11-13 12:32:30","created_by":{"forename":"Micha\u0142","surname":"Kobylski"},"uri":"/api/files/3133677"},"group_uuid":"1936fc5d-b66c-4b21-a8f2-b712cdc61e79"},{"origin":{"id":389650,"publication_date":"2026-10-12"},"id":2823682,"name":"Za\u0142\u0105cznik Nr 1 - Formularz ofertowy.docx","file":{"id":3133679,"name":"Za\u0142\u0105cznik Nr 1 - Formularz ofertowy.docx","created_at":"2026-11-13 12:32:30","created_by":{"forename":"Micha\u0142","surname":"Kobylski"},"uri":"/api/files/3133679"},"group_uuid":"d282e60f-33e6-40ab-a712-bb1dce9c91a6"},{"origin":{"id":389650,"publication_date":"2026-10-12"},"id":2823683,"name":"ZA\u0141\u0104CZNIK NR 3 NDA.docx","file":{"id":3133680,"name":"ZA\u0141\u0104CZNIK NR 3 NDA.docx","created_at":"2026-11-13 12:32:30","created_by":{"forename":"Micha\u0142","surname":"Kobylski"},"uri":"/api/files/3133680"},"group_uuid":"8eeb019a-be6c-4bd4-b722-31a95b39e582"},{"origin":{"id":389650,"publication_date":"2026-10-12"},"id":2823684,"name":"ZA\u0141\u0104CZNIK NR 4 RODO.docx","file":{"id":3133681,"name":"ZA\u0141\u0104CZNIK NR 4 RODO.docx","created_at":"2026-11-13 12:32:30","created_by":{"forename":"Micha\u0142","surname":"Kobylski"},"uri":"/api/files/3133681"},"group_uuid":"30362634-4f79-4182-945e-78e43447ef9a"},{"origin":{"id":389650,"publication_date":"2026-10-12"},"id":2823685,"name":"INQUIRY NO. LERCAN_7_PR_177991_2026-130337-293977.pdf","file":{"id":3133682,"name":"INQUIRY NO. LERCAN_7_PR_177991_2026-130337-293977.pdf","created_at":"2026-11-13 12:32:30","created_by":{"forename":"Micha\u0142","surname":"Kobylski"},"uri":"/api/files/3133682"},"group_uuid":"5212fc6f-50ba-4e1d-976e-7a77d176353c"},{"origin":{"id":389650,"publication_date":"2026-10-12"},"id":2823686,"name":"Att_No. 1 - Offer Form .docx","file":{"id":3133684,"name":"Att_No. 1 - Offer Form .docx","created_at":"2026-11-13 12:32:30","created_by":{"forename":"Micha\u0142","surname":"Kobylski"},"uri":"/api/files/3133684"},"group_uuid":"82438b66-122b-4af6-a6c4-eb814d91e69a"},{"origin":{"id":389650,"publication_date":"2026-10-12"},"id":2823687,"name":"Att_no 3_NDA.docx","file":{"id":3133685,"name":"Att_no 3_NDA.docx","created_at":"2026-11-13 12:32:30","created_by":{"forename":"Micha\u0142","surname":"Kobylski"},"uri":"/api/files/3133685"},"group_uuid":"a673eaa8-6aef-409c-aeca-26dc886cbaa4"},{"origin":{"id":389650,"publication_date":"2026-10-12"},"id":2823688,"name":"Att_no 4_RODO.docx","file":{"id":3133686,"name":"Att_no 4_RODO.docx","created_at":"2026-11-13 12:32:30","created_by":{"forename":"Micha\u0142","surname":"Kobylski"},"uri":"/api/files/3133686"},"group_uuid":"23b9412b-f513-4d09-b5af-fc9a0d1bc0db"},{"origin":{"id":395202,"publication_date":"2026-11-13"},"id":2886009,"name":"Zmiana tre\u015bci ZAPYTANIA OFERTOWEGO","file":{"id":3202861,"name":"Zmiana tre\u015bci ZAPYTANIA OFERTOWEGO .pdf","created_at":"2026-11-13 12:31:07","created_by":{"forename":"Micha\u0142","surname":"Kobylski"},"uri":"/api/files/3202861"},"group_uuid":"72638857-5fce-4cb6-8b65-68bcd5d0b4bb"},{"origin":{"id":395202,"publication_date":"2026-11-13"},"id":2886010,"name":"Change in the content of the REQUEST FOR PROPOSAL","file":{"id":3202863,"name":"Change in the content of the REQUEST FOR PROPOSAL .pdf","created_at":"2026-11-13 12:31:51","created_by":{"forename":"Micha\u0142","surname":"Kobylski"},"uri":"/api/files/3202863"},"group_uuid":"5fd72aa2-88f0-49bc-8f9e-439175572917"}]},"dictionaries":{"announcement_status_draft":1,"announcement_status_published":2},"favorite":null,"badge":null,"offer_set_badge_count":null,"question_badge_count":null}}